Bioxytran, Inc. has introduced optimistic Phase 2 scientific outcomes for its ProLectin-M drug, demonstrating full viral clearance in 100% of sufferers with acute viral infections by the seventh day of remedy.
The scientific research was a randomized, double-blind, placebo-controlled dose-optimization trial, involving 38 individuals who have been administered ProLectin-M in different doses over seven days. The outcomes confirmed statistically important reductions in viral load in comparison with the placebo group, with a p-value of .001.
Key findings revealed that whereas full viral clearance was noticed by Day 7 in all handled topics, some stage of viral non-detection was already measurable by Day 3, with one topic exhibiting non-detection, and by Day 5, this quantity elevated to 16 topics. Importantly, no viral rebounds have been detected throughout a subsequent 14-day post-treatment remark interval.
These outcomes underscore the speedy and efficient viral clearance properties of ProLectin-M. Dr. Leslie Ajayi, Chief Medical Officer of Bioxytran, famous that the trial aimed to replicate real-world remedy timelines and succeeded in demonstrating a statistically significant discount in viral load inside seven days.
The mechanism of motion behind ProLectin-M entails the interference with viral entry on the cell floor, distinguishing it as a novel antiviral strategy that reduces reliance on immune system activation. This extracellular intervention might signify a essentially completely different technique in antiviral remedy, probably broadening the scope of its utility to numerous viral infections.
Following these promising outcomes, Bioxytran plans to have interaction in additional regulatory discussions to assist late-stage scientific trials and discover the effectiveness of ProLectin-M throughout a broader vary of viral indications.
The firm stays dedicated to advancing its novel carbohydrate-based therapeutics in addressing important unmet medical wants inside the discipline of virology.